Patrick C Ma

Patrick C Ma

Auto-generated profile, based on publicly available information

Patrick C Ma

Division of Hematology/Oncology, Department of Medicine, Case Western Reserve University, University Hospitals Case Medical Center, Ireland Cancer Center, and Case Comprehensive Cancer Center, Cleveland, OH

Research Focus & Metrics

Academic Career Length

25Years (2002-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 October 2003
Verified
Journal Article
Closed access
PMPatrick C Ma
Patrick C Ma
TKTakashi Kijima
Takashi Kijima
GMGautam Maulik
Gautam Maulik
EFEdward A Fox
Edward A Fox
MSMartin Sattler
Martin Sattler
Ravi SalgiaRavi Salgia
Ravi Salgia

26 August 2008 in British Journal of Cancer
Verified
Journal Article
Open access
PDF file
ZTZ Tang
Z Tang
RDR Du
R Du
SJS Jiang
S Jiang
CWC Wu
C Wu
DBD S Barkauskas
D S Barkauskas
PMP C Ma
P C Ma
Despite clinical approval of erlotinib, most advanced lung cancer patients are primary non-responders. Initial responders invariably develop secondary resistance, which can be accounted for by T790M-EGFR mutation in half of the relapses. We show that MET is highly expressed in lung cancer, often concomitantly with epidermal growth factor receptor (EGFR), including H1975 cell line. The erlotinib-resistant lung cancer cell line H1975, which expresses L858R/T790M-EGFR in-cis, was used to test for the effect of MET inhibition using the small molecule inhibitor SU11274. H1975 cells express wild-type MET, without genomic amplification (CNV=1.1). At 2 μM, SU11274 had significant in vitro pro-apoptotic effect in H1975 cells, 3.9-fold (P=0.0015) higher than erlotinib, but had no effect on the MET and EGFR-negative H520 cells. In vivo, SU11274 also induced significant tumour cytoreduction in H1975 murine xenografts in our bioluminescence molecular imaging assay. Using small-animal microPET/MRI, SU11274 treatment was found to induce an early tumour metabolic response in H1975 tumour xenografts. MET and EGFR pathways were found to exhibit collaborative signalling with receptor cross-activation, which had different patterns between wild type (A549) and L858R/T790M-EGFR (H1975). SU11274 plus erlotinib/CL-387,785 potentiated MET inhibition of downstream cell proliferative survival signalling. Knockdown studies in H1975 cells using siRNA against MET alone, EGFR alone, or both, confirmed the enhanced downstream inhibition with dual MET–EGFR signal path inhibition. Finally, in our time-lapse video-microscopy and in vivo multimodal molecular imaging studies, dual SU11274-erlotinib concurrent treatment effectively inhibited H1975 cells with enhanced abrogation of cytoskeletal functions and complete regression of the xenograft growth. Together, our results suggest that MET-based targeted inhibition using small-molecule MET inhibitor can be a potential treatment strategy for T790M-EGFR-mediated erlotinib-resistant non-small-cell lung cancer. Furthermore, optimised inhibition may be further achieved with MET inhibition in combination with erlotinib or an irreversible EGFR-TKI.

1 February 2002
Verified
Journal Article
Closed access
GMGautam Maulik
Gautam Maulik
TKTakashi Kijima
Takashi Kijima
PMPatrick C Ma
Patrick C Ma
SGSudip K Ghosh
Sudip K Ghosh
JLJeffrey Lin
Jeffrey Lin
Ravi SalgiaRavi Salgia
Ravi Salgia

1 April 2010 in Clinical Chemistry
Verified
Journal Article
Open access
PDF file
JWJun Wang
Jun Wang
RRRamesh Ramakrishnan
Ramesh Ramakrishnan
ZTZhe Tang
Zhe Tang
WFWeiwen Fan
Weiwen Fan
AKAmy Kluge
Amy Kluge
PMPatrick C Ma
Patrick C Ma
Background: The EGFR [epidermal growth factor receptor (erythroblastic leukemia viral (v-erb-b) oncogene homolog, avian)] gene is known to harbor genomic alterations in advanced lung cancer involving gene amplification and kinase mutations that predict the clinical response to EGFR-targeted inhibitors. Methods for detecting such molecular changes in lung cancer tumors are desirable. Methods: We used a nanofluidic digital PCR array platform and 16 cell lines and 20 samples of genomic DNA from resected tumors (stages I–III) to quantify the relative numbers of copies of the EGFR gene and to detect mutated EGFR alleles in lung cancer. We assessed the relative number of EGFR gene copies by calculating the ratio of the number of EGFR molecules (measured with a 6-carboxyfluorescein–labeled Scorpion™ assay) to the number of molecules of the single-copy gene RPP30 (ribonuclease P/MRP 30kDa subunit) (measured with a 6-carboxy-X-rhodamine–labeled TaqMan™ assay) in each panel. To assay for the EGFR L858R (exon 21) mutation and exon 19 in-frame deletions, we used the ARMS™ and Scorpion technologies in a DxS/Qiagen EGFR29 Mutation Test Kit for the digital PCR array. Results: The digital array detected and quantified rare gefitinib/erlotinib-sensitizing EGFR mutations (0.02%–9.26% abundance) that were present in formalin-fixed, paraffin-embedded samples of early-stage resectable lung tumors without an associated increase in gene copy number. Our results also demonstrated the presence of intratumor molecular heterogeneity for the clinically relevant EGFR mutated alleles in these early-stage lung tumors. Conclusions: The digital PCR array platform allows characterization and quantification of oncogenes, such as EGFR, at the single-molecule level. Use of this nanofluidics platform may provide deeper insight into the specific roles of clinically relevant kinase mutations during different stages of lung tumor progression and may be useful in predicting the clinical response to EGFR-targeted inhibitors.

1 November 2002
Verified
Journal Article
Closed access
TKTakashi Kijima
Takashi Kijima
GMGautam Maulik
Gautam Maulik
PMPatrick C Ma
Patrick C Ma
ETElena V Tibaldi
Elena V Tibaldi
RTRoss E Turner
Ross E Turner
Ravi SalgiaRavi Salgia
Ravi Salgia

25 May 2004
Verified
Journal Article
Closed access
ABAjit Bharti
Ajit Bharti
PMPatrick C Ma
Patrick C Ma
GMGautam Maulik
Gautam Maulik
RSRajeev Singh
Rajeev Singh
EKEshan Khan
Eshan Khan
Ravi SalgiaRavi Salgia
Ravi Salgia